Precision BioSciences Q3 revenue falls sharply

Reuters11-03

Precision BioSciences Q3 revenue falls sharply

Overview

Precision BioSciences Q3 revenue fell sharply
Net loss for Q3 widened compared to the same period last year
Company advances PBGENE-HBV and PBGENE-DMD programs with upcoming clinical milestones

Outlook

Company anticipates IND filing for PBGENE-DMD by end of 2025
Precision expects Phase 1 trial for PBGENE-DMD in 1H 2026
Company projects cash runway into 2H 2027 for clinical milestones

Result Drivers

PBGENE-DMD ADVANCEMENTS - Co highlighted preclinical data showing potential for PBGENE-DMD to restore dystrophin gene in DMD patients
COST REDUCTIONS - Co implemented operating efficiencies to reduce expenses and extend cash runway

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue		$13,000
Q3 Net Income		-$21.77 mln
Q3 Income from Operations		-$20.66 mln
Q3 Operating Expenses		$20.68 mln

Press Release: ID:nBw8T69PHa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580297704?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580297704","market":"nz","top_or_hot":-1,"title":"Precision BioSciences Q3 revenue falls sharply","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Precision BioSciences Q3 revenue falls sharply</title></head><body><p><span>Overview</span></p><ul><li><p>Precision BioSciences Q3 revenue fell sharply</p></li><li><p>Net loss for Q3 widened compared to the same period last year</p></li><li><p>Company advances PBGENE-HBV and PBGENE-DMD programs with upcoming clinical milestones</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company anticipates IND filing for PBGENE-DMD by end of 2025</p></li><li><p>Precision expects Phase 1 trial for PBGENE-DMD in 1H 2026</p></li><li><p>Company projects cash runway into 2H 2027 for clinical milestones</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PBGENE-DMD ADVANCEMENTS - Co highlighted preclinical data showing potential for PBGENE-DMD to restore dystrophin gene in DMD patients</p></li><li><p>COST REDUCTIONS - Co implemented operating efficiencies to reduce expenses and extend cash runway</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$13,000</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$21.77 mln</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$20.66 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$20.68 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw8T69PHa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precision BioSciences Q3 revenue falls sharply</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecision BioSciences Q3 revenue falls sharply\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-03 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Precision BioSciences Q3 revenue falls sharply</title></head><body><p><span>Overview</span></p><ul><li><p>Precision BioSciences Q3 revenue fell sharply</p></li><li><p>Net loss for Q3 widened compared to the same period last year</p></li><li><p>Company advances PBGENE-HBV and PBGENE-DMD programs with upcoming clinical milestones</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company anticipates IND filing for PBGENE-DMD by end of 2025</p></li><li><p>Precision expects Phase 1 trial for PBGENE-DMD in 1H 2026</p></li><li><p>Company projects cash runway into 2H 2027 for clinical milestones</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PBGENE-DMD ADVANCEMENTS - Co highlighted preclinical data showing potential for PBGENE-DMD to restore dystrophin gene in DMD patients</p></li><li><p>COST REDUCTIONS - Co implemented operating efficiencies to reduce expenses and extend cash runway</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$13,000</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$21.77 mln</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$20.66 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$20.68 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw8T69PHa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DTIL","symbol_name":"Precision Biosciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL1N3WF0DV:1","article_id":"2580297704","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580297704","pubTimestamp":1762171831,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Precision BioSciences Q3 revenue falls sharplyOverviewPrecision BioSciences Q3 revenue fell sharplyNet loss for Q3 widened compared to the same period last yearCompany advances PBGENE-HBV and PBGENE-D","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DTIL":"Precision Biosciences Inc","BK4139":"生物科技"},"translate_title":"Precision BioSciences第三季度收入大幅下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DTIL":0.9},"content_text":"Precision BioSciences Q3 revenue falls sharplyOverviewPrecision BioSciences Q3 revenue fell sharplyNet loss for Q3 widened compared to the same period last yearCompany advances PBGENE-HBV and PBGENE-DMD programs with upcoming clinical milestonesOutlookCompany anticipates IND filing for PBGENE-DMD by end of 2025Precision expects Phase 1 trial for PBGENE-DMD in 1H 2026Company projects cash runway into 2H 2027 for clinical milestonesResult DriversPBGENE-DMD ADVANCEMENTS - Co highlighted preclinical data showing potential for PBGENE-DMD to restore dystrophin gene in DMD patientsCOST REDUCTIONS - Co implemented operating efficiencies to reduce expenses and extend cash runwayKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Revenue$13,000Q3 Net Income-$21.77 mlnQ3 Income from Operations-$20.66 mlnQ3 Operating Expenses$20.68 mlnPress Release: ID:nBw8T69PHaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580297704","isCrawlerRequest":true}